SCHEMBL2746561

SCHEMBL2746561

C[C@](O)(COc1ccc(F)cc1)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
AR P10275 5/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14086825 1.00 AR (1.00) AR
SCHEMBL3698441 1.00 AR (1.00) AR
SCHEMBL12706742 0.92 AR (0.85) AR
SCHEMBL14252926 0.92 AR (0.85) AR
SCHEMBL12453355 0.91 AR (0.83) AR
SCHEMBL10364518 0.91 AR (0.83) AR
SCHEMBL2689756 0.91 AR (1.00) AR
SCHEMBL16871452 0.91 AR (1.00) AR
SCHEMBL12451560 0.91 AR (0.83) AR
SCHEMBL14086827 0.91 AR (0.83) AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2276496-B1 THERAPEUTIC MODULATION OF OCULAR SURFACE LUBRICATION UNIV CALIFORNIA (US) 2019-07-10 EP claimed
US-9138457-B2 Therapeutic modulation of ocular surface lubrication THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-09-22 US claimed
WO-2009137602-A1 THERAPEUTIC MODULATION OF OCULAR SURFACE LUBRICATION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-11-12 WO claimed
EP-2276497-B1 OPHTHALMIC DEVICE, AND METHOD OF USE THEREOF, FOR INCREASING OCULAR BOUNDARY LUBRICATION UNIV CALIFORNIA (US) 2020-04-22 EP disclosed
EP-2276496-B1 THERAPEUTIC MODULATION OF OCULAR SURFACE LUBRICATION UNIV CALIFORNIA (US) 2019-07-10 EP disclosed
US-9682093-B2 Compositions and methods for treating or preventing metabolic syndrome disorders CHARLES R. DREW UNIVERSITY OF MEDICINE AND SCIENCE (US) 2017-06-20 US disclosed
EP-2464375-B1 PRG4 TREATMENT FOR INTERSTITIAL CYSTITIS LUBRIS LLC (US) 2017-06-14 EP disclosed
US-9493403-B2 Treating androgen decline in aging male (ADAM)-associated conditions with SARMs UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2016-11-15 US disclosed
US-9493403-B2 Treating androgen decline in aging male (ADAM)-associated conditions with SARMs UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2016-11-15 US disclosed
EP-2289503-B1 Treating muscle wasting with selective androgen receptor modulators UNIV TENNESSEE RES FOUNDATION (US) 2016-06-29 EP disclosed
US-9138457-B2 Therapeutic modulation of ocular surface lubrication THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-09-22 US disclosed
US-20070173546-A1 Selective androgen receptor modulators and method of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2007-07-26 US disclosed
WO-2007081696-A2 TREATING ANDROGEN DECLINE IN AGING MALE (ADAM)-ASSOCIATED CONDITIONS WITH SARMS GTX, INC. (US) 2007-07-19 WO disclosed
US-20070161608-A1 Selective androgen receptor modulators for treating muscle wasting UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2007-07-12 US disclosed
US-20070161608-A1 Selective androgen receptor modulators for treating muscle wasting UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2007-07-12 US disclosed
US-20070123563-A1 Selective androgen receptor modulators and method of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2007-05-31 US disclosed
US-20070123563-A1 Selective androgen receptor modulators and method of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2007-05-31 US disclosed
US-7205437-B2 Selective androgen receptor modulators UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2007-04-17 US disclosed
US-7205437-B2 Selective androgen receptor modulators UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2007-04-17 US disclosed
US-20070066568-A1 Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2007-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070173546-A1 Selective androgen receptor modulators and method of use thereof AR, SHBG, ESRRA AR 1/4885
US-20070066568-A1 Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators AR, SARM1, OPRM1 AR 1/4885
US-20070123563-A1 Selective androgen receptor modulators and method of use thereof AR, SHBG, ESRRA AR 1/4885
US-20070161608-A1 Selective androgen receptor modulators for treating muscle wasting AR, ESRRA, SHBG AR 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.